The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Beam Therapeutics Inc shares valued at $12,246 were sold by FMR LLC on Oct 27 ’25. At $26.68 per share, FMR LLC sold 459 shares. The insider’s holdings dropped to 14 shares worth approximately $303.24 following the completion of this transaction.
Also, Cavanagh Bethany J sold 467 shares, netting a total of over 11,456 in proceeds. Following the sale of shares at $24.53 each, the insider now holds 44,045 shares.
Before that, Bellon Christine had sold 373 shares from its account. In a trade valued at $9,150, the Chief Legal Officer traded Beam Therapeutics Inc shares for $24.53 each. Upon closing the transaction, the insider’s holdings decreased to 373 shares, worth approximately $2.53 million.
As published in their initiating research note from Jefferies on October 09, 2025, Beam Therapeutics Inc [BEAM] has been a Buy and the price target has been revised to $41. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late March. As of March 10, 2025, Scotiabank has increased its “Sector perform” rating to a “Sector outperform” for BEAM. Earlier on January 29, 2025, Cantor Fitzgerald upgraded its rating. Their new recommendation was “an Overweight” for BEAM stock which previously was a “a Neutral”.
Analyzing BEAM Stock Performance
On last trading session, Beam Therapeutics Inc [NASDAQ: BEAM] plunged -0.96% to $21.66. The stock’s lowest price that day was $21.162, but it reached a high of $24.08 in the same session. During the last five days, there has been a drop of approximately -6.44%. Over the course of the year, Beam Therapeutics Inc shares have dropped approximately -28.63%. Shares of the company reached a 52-week high of $35.25 on 02/18/25 and a 52-week low of $13.52 on 04/07/25.
Support And Resistance Levels for Beam Therapeutics Inc (BEAM)
According to the 24-hour chart, there is a support level at 20.52, which, if violated, would cause prices to drop to 19.38. In the upper region, resistance lies at 23.44. The next price resistance is at 25.22. RSI (Relative Strength Index) is 39.11 on the 14-day chart, showing neutral technical sentiment.
Is Beam Therapeutics Inc subject to short interest?
Stocks of Beam Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -1.56 million shares to 19.82 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 21.38 million shares. A decline of -7.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.83 of the overall float, the days-to-cover ratio (short ratio) decline to 7.83.
Which companies own the most shares of Beam Therapeutics Inc (BEAM)?
In terms of Beam Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 41 in the next 12 months, up nearly 87.47% from the previous closing price of $21.87. Analysts anticipate Beam Therapeutics Inc stock to reach 41 by 2025, with the lowest price target being 41. In spite of this, 6 analysts ranked Beam Therapeutics Inc stock as Buy at the end of 2025. On November 06, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and upgraded coverage with a $39.
